52.39
2.03%
1.04
After Hours:
52.39
Rhythm Pharmaceuticals Inc stock is traded at $52.39, with a volume of 219.60K.
It is up +2.03% in the last 24 hours and up +10.78% over the past month.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.
See More
Previous Close:
$51.35
Open:
$51.17
24h Volume:
219.60K
Relative Volume:
0.51
Market Cap:
$3.18B
Revenue:
$91.93M
Net Income/Loss:
$-273.87M
P/E Ratio:
-15.97
EPS:
-3.28
Net Cash Flow:
$-140.47M
1W Performance:
+2.60%
1M Performance:
+10.78%
6M Performance:
+20.91%
1Y Performance:
+128.53%
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Name
Rhythm Pharmaceuticals Inc
Sector
Industry
Phone
857-264-4280
Address
222 BERKELEY STREET, BOSTON, MA
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-08-24 | Downgrade | BofA Securities | Buy → Neutral |
Dec-19-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
Aug-01-23 | Upgrade | BofA Securities | Neutral → Buy |
Jan-18-23 | Resumed | Canaccord Genuity | Buy |
Aug-08-22 | Upgrade | Goldman | Neutral → Buy |
Aug-05-22 | Upgrade | BofA Securities | Underperform → Neutral |
Jun-17-22 | Reiterated | Needham | Buy |
Mar-02-22 | Resumed | Stifel | Buy |
Feb-17-22 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
Dec-08-21 | Initiated | Wells Fargo | Overweight |
Nov-19-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
Sep-14-21 | Resumed | Goldman | Neutral |
Aug-04-21 | Downgrade | BofA Securities | Neutral → Underperform |
Aug-04-21 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
Nov-30-20 | Downgrade | BofA Securities | Buy → Neutral |
Jan-08-20 | Initiated | Goldman | Sell |
Jul-12-19 | Upgrade | Stifel | Hold → Buy |
Jul-08-19 | Initiated | Canaccord Genuity | Buy |
Mar-13-19 | Initiated | Ladenburg Thalmann | Buy |
Sep-07-18 | Resumed | Morgan Stanley | Overweight |
Jun-25-18 | Reiterated | Needham | Buy |
Jun-15-18 | Reiterated | Needham | Buy |
Oct-30-17 | Initiated | BofA/Merrill | Buy |
Oct-30-17 | Initiated | Needham | Buy |
View All
Rhythm Pharmaceuticals Inc Stock (RYTM) Latest News
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is Perceptive Advisors LLC's 6th Largest Position - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is Frazier Life Sciences Management L.P.'s 6th Largest Position - MarketBeat
Driehaus Capital Management LLC Raises Stock Position in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Shares Sold by Profund Advisors LLC - MarketBeat
Canada Pension Plan Investment Board Has $17.12 Million Stake in Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) - MarketBeat
Is Rhythm Pharmaceuticals (NASDAQ:RYTM) Using Debt Sensibly? - Simply Wall St
Rhythm: Upcoming sNDA Label Expansion IMCIVREE Isn't Only Catalyst On Deck (NASDAQ:RYTM) - Seeking Alpha
Long Term Trading Analysis for (RYTM) - Stock Traders Daily
Rhythm Pharmaceuticals, Inc. (RYTM): Short Seller Sentiment is Bearish - Insider Monkey
Rhythm Pharmaceuticals, Inc. (RYTM): Short Seller Sentiment is Bearish - Yahoo Finance
Rhythm Pharmaceuticals Inc. [RYTM] Shares Jump Approximately 128.63% Over the Year - Knox Daily
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength? - MSN
Algorhythm Gains on Role in Buyside Conference - Baystreet.ca
Rhythm Pharmaceuticals announces voting results By Investing.com - Investing.com Australia
Equities Analysts Issue Forecasts for Rhythm Pharmaceuticals, Inc.'s Q3 2024 Earnings (NASDAQ:RYTM) - MarketBeat
Rhythm Pharma draws bullish view at JMP on opportunity in rare genetic obesities - MSN
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Director Jennifer L. Good Sells 31,751 Shares - MarketBeat
Rhythm Pharmaceuticals announces voting results - Investing.com India
Rhythm Pharmaceuticals announces voting results By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals announces voting results - Investing.com
Rhythm pharmaceuticals director Jennifer Good sells over $1.6m in stock - Investing.com Australia
Rhythm pharmaceuticals director Jennifer Good sells over $1.6m in stock - Investing.com Canada
Rhythm pharmaceuticals director Jennifer Good sells over $1.6m in stock - Investing.com India
Rhythm pharmaceuticals director Jennifer Good sells over $1.6m in stock - Investing.com
How should investors view Rhythm Pharmaceuticals Inc. (RYTM)? - US Post News
Rhythm Pharmaceuticals (NASDAQ:RYTM) Receives New Coverage from Analysts at HC Wainwright - Defense World
Rhythm Pharmaceuticals (NASDAQ:RYTM) Reaches New 52-Week High at $54.88 - MarketBeat
HC Wainwright Begins Coverage on Rhythm Pharmaceuticals (NASDAQ:RYTM) - MarketBeat
Strength Seen in Rhythm Pharmaceuticals (RYTM): Can Its 7.4% Jump Turn into More Strength? - Yahoo Finance
What 4 Analyst Ratings Have To Say About Rhythm Pharmaceuticals - Benzinga
Rhythm Pharmaceuticals initiated with a Buy at H.C. Wainwright - TipRanks
Rhythm Pharma stock soars to all-time high of $53.98 By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals (NASDAQ:RYTM) Trading Up 6.1% - MarketBeat
Rhythm Pharma stock soars to all-time high of $53.98 - Investing.com India
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Position Reduced by Primecap Management Co. CA - MarketBeat
Rhythm Pharma stock draws bullish view at JMP (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharma stock soars to all-time high of $53.98 - Investing.com
Rhythm Pharma stock soars to all-time high of $53.98 By Investing.com - Investing.com UK
Rhythm Pharmaceuticals (NASDAQ:RYTM) Receives New Coverage from Analysts at JMP Securities - MarketBeat
JMP Securities highlights Imcivree's role in Rhythm Pharmaceuticals stock outlook - Investing.com Canada
Rhythm Pharmaceuticals initiated with an Outperform at JMP Securities - TipRanks
JMP Securities highlights Imcivree's role in Rhythm Pharmaceuticals stock outlook - Investing.com
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - GlobeNewswire
Rhythm Pharmaceuticals Announces New Employment Inducement Grants - StockTitan
Take off with Rhythm Pharmaceuticals Inc. (RYTM): Get ready for trading - SETE News
Rhythm Pharmaceuticals Inc. (RYTM)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - The Dwinnex
Rhythm Pharmaceuticals director Jennifer Good sells over $1.8m in stock - Investing.com India
Rhythm Pharmaceuticals director sells over $1m in company stock By Investing.com - Investing.com Australia
Rhythm Pharmaceuticals executive sells over $205k in company stock By Investing.com - Investing.com Australia
Rhythm Pharmaceuticals director sells over $1m in company stock - Investing.com
Rhythm Pharmaceuticals executive sells over $205k in company stock - Investing.com India
Rhythm Pharmaceuticals Inc Stock (RYTM) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):